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The first version of the Standard PREanalytical Code (SPREC) was developed in 2009 by the International
Society for Biological and Environmental Repositories (ISBER) Biospecimen Science Working Group to facilitate
documentation and communication of the most important preanalytical quality parameters of different types of
biospecimens used for research. This same Working Group has now updated the SPREC to version 2.0, pre-
sented here, so that it contains more options to allow for recent technological developments. Existing elements
have been fine tuned. An interface to the Biospecimen Reporting for Improved Study Quality (BRISQ) has been
defined, and informatics solutions for SPREC implementation have been developed. A glossary with SPREC-
related definitions has also been added.
Introduction
The SPREC (Standard PREanalytical Code) was de-veloped in 2009 to provide a comprehensive and easy-
to-implement tool to document the in vitro preanalytical
(collection, processing and storage) details of biospecimens.1
The objective of the SPREC is to facilitate annotation of
biospecimens with preanalytical factors that fulfill two cri-
teria: (a) their variation is known or highly suspected to
impact the results of downstream analyses, and (b) they are
within the control of the biobank and thus can be anticipated
and standardized in standard operating procedures (SOPs).
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Table 1. Preanalytical Variables Included in SPREC
(7-element long SPREC), Version SPREC 2.0,
Applied to Fluid Samples
Type of sample
Ascites fluid ASC
Amniotic fluid AMN
Bronchoalveolar lavage BAL
Blood (whole) BLD
Bone marrow aspirate BMA
Breast milk BMK
Buccal cells BUC
Unficolled buffy coat, viable BUF
Unficolled buffy coat, nonviable BFF
Ficoll mononuclear cells, viable CEL
Fresh cells from nonblood specimen type CEN
Cells from nonblood specimen type
(e.g., ascites, amniotic), viable
CLN
Cord blood CRD
Cerebrospinal fluid CSF
Dried whole blood (e.g., Guthrie cards) DWB
Nasal washing NAS
Ficoll mononuclear cells, nonviable PEL
Cells from non blood specimen type
(e.g., ascites, amniotic), nonviable
PEN
Pleural fluid PFL
Plasma, single spun PL1
Plasma, double spun PL2
Red blood cells RBC
Saliva SAL
Semen SEM
Serum SER
Sputum SPT
Stool STL
Synovial fluid SYN
Tears TER
24 h urine U24
Urine, random ð‘‘spot00Þ URN
Urine, first morning URM
Urine, timed URT
Other ZZZ
Type of primary container
Acid citrate dextrose ACD
Additives ADD
Serum tube without clot activator CAT
Citrate phosphate dextrose CPD
Cell Preparation Tube CPT
EDTA and gel EDG
Lithium heparin HEP
Hirudin HIR
Lithium heparin and gel LHG
Oragene collection container or equivalent ORG
PAXgene blood RNA + PAX
Potassium EDTA PED
Polyethylene tube sterile PET
S8820 protease inhibitor tablets or equivalent PI1
Protease inhibitors PIX
Polypropylene tube sterile PPS
PAXgene blood DNA PXD
PAXgene bone marrow RNA PXR
Sodium citrate SCI
Sodium EDTA SED
Sodium heparin SHP
Sodium fluoride/potassium oxalate SPO
Serum separator tube with clot activator SST
(continued)
Table 1. (Continued)
Type of primary container (Cont.)
Tempus tube TEM
Trace elements tube TRC
Unknown XXX
Other ZZZ
Pre-centrifugation (delay between collection and processing)
RT* < 2 h A
2C–10C < 2 h B
RT 2–4 h C
2C–10C 2–4h D
RT 4–8h E
2C–10C 4–8h F
RT 8–12 h G
2C–10C 8–12h H
RT 12–24 h I
2C–10C 12–24 h J
RT 24–48 h K
2C–10C 24–48 h L
RT > 48 h M
2C–10C > 48 h N
35C–38C < 2 h O
Unknown X
Other Z
Centrifugation
RT 10–15 min < 3000 g no braking A
RT 10–15 min < 3000 g with braking B
2C–10 C 10–15 min < 3000 g no braking C
2C–10 C 10–15 min < 3000 g with braking D
RT 10–15 min 3000–6000 g with braking E
2C–10C 10–15 min 3000 g to 6000 g with braking F
RT 10–15 min 6000 g to 10000 g with
braking
G
2C–10 C 10–15 min 6000 g to 10000 g with
braking
H
RT 10–15 min > 10000 g with braking I
2C–10 C 10–15 min > 10000 g with braking J
RT 30min < 1000 g no braking M
No centrifugation N
Unknown X
Other Z
Second centrifugation
RT 10–15 min < 3000 g no braking A
RT 10–15 min < 3000 g with braking B
2C–10C 10–15 min < 3000 g no braking C
2C–10C 10–15 min < 3000 g with braking D
RT 10–15 min 3000–6000 g with braking E
2C–10C 10–15 min 3000–6000 g with braking F
RT 10–15 min 6000–10,000 g with braking G
2C–10C 10–15 min 6000–10,000 g with braking H
RT 10–15 min > 10,000 g with braking I
2C–10C 10–15 min > 10,000 g with braking J
No centrifugation N
Unknown X
Other Z
Post-centrifugation delay
< 1 h 2C–10C A
< 1 h RT B
1 to 2 h 2C–10C C
(continued)
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The original SPREC is applicable to animal biospecimens,
and more specifically to mammals. SPREC development in
botanical collections and storage has also been explored.2
Since then and as originally anticipated, new technologies
have been developed for specimen collection (e.g., new anti-
coagulants), processing (e.g., new tissue stabilization meth-
ods), and storage (e.g., new dry, room temperature storage
media) necessitating an update of the original codes. Further-
more, with the implementation of SPREC version 1.0 in dif-
ferent biobanks, feedback has been received and suggestions
on possible improvements considered. We are aware of at least
thirteen biobanks or biobank networks in the United States,
Europe, Korea, and Australia,3 and of at least three commercial
biobank LIMS who have already implemented the SPREC
(personal communications). The SPREC has been incorporated
in the ‘‘Minimum data set for sharing biobank samples, in-
formation, and data’’ (MIABIS), developed by the Biobanking
and Biomolecular Resources Research Infrastructure Sweden
(BBMRI.se)4 and is also being implemented as a national
standard both for healthcare and research in BBMRI.se (per-
sonal communication). An application programming inter-
face (API) module has been developed that allows SPREC to
be defined from sample collection and processing protocols,
submitted to the Molecular Methods database (www
.molmeth.org) that is supported by BBMRI.5 Furthermore,
SPREC is mentioned in the College of American Pathologists
(CAP) biobank accreditation checklist, which is being
tested in pilot audits (personal communication). Currently,
the application of SPREC to stem cell biobanks is being
evaluated by Demiroglu and colleagues at the University
Medical Center in Go¨ttingen, Germany (manuscript in
preparation). Thus, this new version 2.0 has been developed,
and is expected to be more comprehensive and easier to
implement.
SPREC Version 2.0
In updating SPREC 1.0, and for the sake of continuity, no
significant changes to codes were made, while new options
have been added as detailed in Tables 1 and 2. The new
options in SPREC 2.0 include the following:
Fluid samples
Sample types. Dried whole blood (e.g., Guthrie cards)
and red blood cell fraction were added. A distinction was
made between random, timed, and first morning urine
specimen.
Types of primary containers. Sodium-heparin collection
tube, EDTA, and heparin collection tubes with a gel sepa-
ration plug and cell preparation tubes (CPT) were added. A
distinction was made between serum separation tubes with
silica clot activator and tubes without additive. No distinc-
tion is now made between evacuated (Vacutainer-type) and
nonevacuated (Monovette-type) collection tubes. Poly-
ethylene containers (often used for urine collection) and ad-
ditives (often used in urine collection) were added.
Centrifugation conditions. Initial centrifugation conditions
of 30min at room temperature (RT) with a relative G-force
< 1000 g and without braking used (most appropriate for
density centrifugation and isolation of mononuclear cells)
were added. For all the centrifugation options, a 10-min
centrifugation time was replaced by 10–15min to provide
more flexibility. A ‘‘not applicable’’ option in the post-cen-
trifugation element was added.
Storage conditions. Long-term storage options were in-
cluded for liquid nitrogen preceded by temporary - 80C
storage (in either cryotubes or straws). The temperature op-
tions for paraffin blocs were revised from ‘‘RT’’ only to ‘‘RT
or 2C–10C’’. Other new storage options include a dry
technology medium at RT, bag storage, original primary
container, and tubes from 40–500 mL sizes. Storage at refrig-
erated temperatures has been harmonized throughout the
SPREC and corresponds to 2C–10C.
Table 1. (Continued)
Post-centrifugation delay (Cont.)
1 to 2 h 2C–10C C
1 to 2 h RT D
2 to 8 h 2C–10C E
2 to 8 h RT F
8 to 24 h 2C–10C G
8 to 24 h RT H
> 24 h 2C–10C I
> 24 h RT J
Not applicable N
Unknown X
Other Z
Long-term storage
PP tube 0.5- to 2mL** ( - 85)C–( - 60)C A
PP tube 0.5- to 2mL ( - 35)C–( - 18)C B
PP tube 0.5- to 2mL < -135C V
Cryotube 1- to 2mL LN*** C
Cryotube 1- to 2mL ( - 85)C–( - 60) C D
Cryotube 1- to 2-mL Programmable
freezing to < -135C
E
Plastic cryo straw LN*** F
Straw ( - 85)C–( - 60)C G
Straw ( - 35)C–( - 18)C H
Straw Programmable
freezing to < -135C
I
PP tube ‡ 5mL ( - 85)C–( - 60)C J
PP tube ‡ 5mL ( - 35)C–( - 18)C K
Microplate ( - 85)C–( - 60)C L
Microplate ( - 35)C–( - 18)C M
Cryotube 1- to 2mL LN*** after temporary
( - 85)C–( - 60)C
N
Plastic cryo straw LN*** after temporary
( - 85)C–( - 60)C
O
Paraffin block RT or 2C 10C P
Bag LN*** Q
Dry technology medium RT R
PP tube 40- to 500 mL ( - 85)C–( - 60)C S
PP tube 40- to 500 mL ( - 35)C–( - 18)C T
PP tube 40- to 500 mL < -135C W
Original primary container ( - 35)C–( - 18)C
or (- 85)C–(- 60)C
Y
Unknown X
Other Z
New elements are screened. Codes in bold come from the
Laboratory Data Management System (LDMS).
*RT, room temperature: 18C–28C; **PP, polypropylene; ***LN,
liquid nitrogen, referring to either vapor- or liquid-phase (this
information being documented in the biobank’s SOPs)
Volumes refer to container size.
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Table 2. Preanalytical Variables Included
in the SPREC (7-element long SPREC), Version
SPREC 2.0, Applied to Solid Samples
Type of sample
Fresh cells from non blood
specimen type (e.g., biopsy)
CEN
Cells from non blood specimen
type (e.g., dissociated tissue), viable
CLN
Cells from fine needle aspirate FNA
Hair HAR
Cells from laser capture
microdissected tissue
LCM
Cells from non blood specimen type
(e.g., dissociated tissue), nonviable
PEN
Placenta PLC
Solid tissue TIS
Disrupted tissue, non-viable TCM
Other ZZZ
Type of collection
Autopsy < 6 h postmortem A06
Autopsy 6–12 h postmortem A12
Autopsy 12–24 h postmortem A24
Autopsy 24–48 h postmortem A48
Autopsy 48–72 h postmortem A72
Biopsy in culture media BCM
Biopsy BPS
Biopsy in normal saline or
phosphate buffered saline
BSL
Biopsy in tissue low temperature
transport media
BTM
Fine needle aspirate FNA
Punction PUN
Surgical excision in culture media SCM
Surgical excision SRG
Surgical excision in normal
saline or phosphate buffered saline
SSL
Surgical excision in tissue low
temperature transport media
STM
Surgical excision in vacuum container VAC
Swab SWB
Other ZZZ
Warm ischemia time
< 2min A
2–10min B
10–20min C
20–30min D
30–60min E
> 60min F
Unknown X
Not applicable (e.g., biopsy) N
Other Z
Cold ischemia time
< 2min A
2–10min B
10–20min C
20–30min D
30–60min E
> 60min F
Unknown X
Not applicable (e.g., autopsy) N
Other Z
(continued)
Table 2. (Continued)
Fixation/stabilization type
Non-aldehyde with acetic acid ACA
Aldehyde-based ALD
Allprotect tissue reagent ALL
Alcohol-based ETH
Nonbuffered formalin FOR
Heat stabilization HST
Snap freezing SNP
Non-aldehyde based without acetic acid NAA
Neutral buffered formalin NBF
Optimum cutting temperature medium OCT
PAXgene tissue PXT
RNA Later RNL
Unknown XXX
Other ZZZ
Fixation time
< 15min A
15min–1 h B
1–4 h C
4–8h D
8–24 h E
24–48 h F
48–72 h G
Not applicable N
Unknown X
Other Z
Long-term storage
PP tube 0.5–2mL** (- 85)C–( - 60)C A
PP tube 0.5–2mL (- 35)C–( - 18)C B
PP tube 0.5–2mL < -135C V
Cryotube 1–2mL Liquid nitrogen*** C
Cryotube 1–2mL (- 85)C–( - 60)C D
Cryotube 1–2mL Programmable
freezing to < -135C
E
Plastic cryostraw Liquid nitrogen F
Straw (- 85)C–( - 60)C G
Straw (- 35)C–( - 18)C H
Straw Programmable
freezing to < -135C
I
PP tube ‡ 5mL (- 85)C–( - 60)C J
PP tube ‡ 5mL (- 35)C–( - 18)C K
Microplate (- 85)C–( - 60)C L
Microplate (- 35)C–( - 18)C M
Cryotube 1–2mL LN*** after temporary
(- 85)C–(- 60)C
N
Straw LN*** after temporary
(- 85)C–(- 60)C
O
Paraffin block RT or 2C 10C P
Bag LN*** Q
Dry technology medium RT R
PP tube 40–500 mL (- 85)C–( - 60)C S
PP tube 40–500 mL (- 35)C–( - 18)C T
PP tube 40–500 mL < -135  C W
Original primary container (- 35)-(- 18)C
or (- 85)-( - 60) C
Y
Unknown X
Other Z
New elements are screened. Codes in bold come from the
Laboratory Data Management System (LDMS).
*RT, room temperature: 18C–28C; **PP, polypropylene; ***Li-
quid nitrogen refers to either vapor or liquid phase (this information
being documented in the biobank’s SOPs)
Volumes refer to container size.
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Solid samples
Sample types. Placenta was added as a new sample type.
The abbreviation LCM appeared twice in the sample type
element in version 1.0. In version 2.0, LCM corresponds to
cells from laser capture microdissected tissue, while TCM
corresponds to cells from mechanically disrupted tissue.
For biopsies and surgical excisions, options for collection
(and subsequent transport) in either saline, culture media, or
low-temperature transportmedia (e.g., AQIX,Hyperthermosol,
Unisol, Thermo-ROS) or in vacuum containers were added.
‘‘Fixation’’ type became ‘‘fixation/stabilization’’ type and
now includes heat stabilization, PAXgene tissue fixation,
and Allprotect tissue fixation/stabilization options.
A ‘‘not applicable’’ option was added in the Fixation time
element.
Support Tools for Implementation
of SPREC Version 2.0
The integration of SPREC into biobank databases gener-
ally requires the inclusion of SPREC drop-lists among the
‘‘tables’’ in the software. This is relatively easy with cus-
tomized software, but the supplier would need to make a
customized development for off-the-shelf software. Two
tools have been developed in order to facilitate SPREC im-
plementation and interfacing with either customized or off-
the-shelf biobank software.
A default SPREC can be set per sample type according to
the SOPs of the collection project. Thus, only deviations from
the SOP SPREC need to be documented. These can be
highlighted, making any deviation from pre-defined sample
quality or any nonconforming in processing directly visible.
However, active generation of the SPREC for each individual
sample is to be preferred as it enforces traceability.
Although the use of the SPREC requires an additional
initial investment of time, it is expected that this will be more
than repaid by the ease and accuracy of subsequent sample
search and selection.
SPRECware
The first tool (SPRECware) requires entry of each sam-
ples’ SPREC elements. SPRECware6 is an IT architecture,
that is, a collection of software and communication tools
that have been developed in order to foster the adoption of
SPREC by biobanks and biolaboratories. Basic information
concerning preanalytical processing of a given sample is
selected from drop-down menus. The resulting SPREC is
generated together with the corresponding barcode, and all
the preanalytical data with the SPREC are stored in a local
database.
One component, SPRECbase, has been recently released
and is freely downloadable from http://www.sprecware
.org. This software supports both coding/printing barcode
labels and decoding in text of a sample’s SPREC, then storing
all the preanalytical data in a local database. These barcodes
simplify storing and exchanging corresponding information
about the samples.
In a working environment, SPRECware is intended to be
connected to the laboratory/biobank information system
(LIS/BIS). The required data can then be loaded from the
originating biobank’s LIS/BIS database and translated into
the SPREC. Samples are thus labeled with both the human-
readable and barcoded format. The barcode provides the
receiver organization with the data documenting the spec-
imen and can be stored in the LIS/BIS. This approach
provides fully automated data transfer without manual
writing or reading when the organizations exchanging
specimens both use SPREC. In the case that the receiving
organization has not adopted the SPREC, it is still possible
to read the SPREC (e.g., by a barcode scanner) and down-
load the explicit preanalytical data by means of an internet
connection.
Since the SPREC does not encapsulate any personal data, it
can be used for searches on sample availability. This possibility
of a preliminary check would allow a researcher to select ma-
terial with the most appropriate preanalytical characteristics for
a planned experiment.6 (Even in the case of derivatives (e.g.,
DNA, RNA), the SPREC information on the collected samples,
from which derivatives were produced, is highly valuable.
SPRECalc
Unlike the SPRECware which requires entry of the SPREC
options (A, B, X.), the second tool (SPRECalc) requires
entry of the corresponding preanalytical variables them-
selves (temperature, time.); this tool then performs auto-
matic calculation of the time-associated elements and
generation of SPREC.
The Excel-based SPRECalc automatically calculates
SPREC time-associated elements for solid and fluid samples,
using the data logic depicted in Figures 1 and 2. Data entry is
supported by pull-down lists (blue-colored fields in the Excel
tool) to minimize inconsistent data entry. The dropdowns are
based upon SPREC version 2.0 as specified in this article and
are provided in the ‘‘Lists’’ worksheet. Time stamps have to
be entered in the format dd/mm/yyyy hh:mm:ss (pink-
colored fields in the Excel tool) to allow correct calculation of
time spans. The format of the related columns is pre-defined.
To ensure that automatic SPREC calculation and genera-
tion can be performed, the data items in Table 3 must be
either captured manually or retrieved automatically (i.e., via
barcode scanning or RFID tagging).
Gray fields contain automatic calculations/translations,
displaying either the time period (e.g., warm/cold ischemia
time, fixation time), or ‘‘help’’ columns for identification of
the applicable SPREC.
For solid samples, the fixation time can be determined in
two different ways. Option 1 is designed for use with auto-
mated fixation systems (fixation start time, program type,
and program start time need to be recorded). Option 2 is
targeted for nonautomated fixation steps (fixation start and
end time need to be entered).
With respect to option 1, the ‘‘Fixation Programs’’
worksheet allows the user to predefine fixation programs and
their respective duration. Selection of the applicable program
during data entry automatically uses the related duration to
calculate the correct fixation time, provided fixation start time
and program start time have been entered as well. For each
sample, SPREC is then automatically displayed following the
coding rules specified in this article. All of these fields are
protected against changes.
The tool also contains the following quality-related fea-
tures. The data entry worksheet provides its own ‘‘quality
control’’ features, since Excel-specific error messages in the
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calculated columns (e.g., ###### or #REF) indicate data in-
consistency (e.g., the fixation start time entered is before the
collection time). Systematic investigation of such errors sup-
ports quality checks to improve data quality and consistency.
Default SPRECs can be defined for each collection ac-
cording to established SOPs for sample collection. Non-
conformities can be detected automatically by the system
and flagged in dedicated columns, with a flexible way of
setting target parameters (e.g., fixation time shall be
< = 24 h). Alternatively the same nonconformities can be
specifically custom-programmed directly in the final SPREC
columns, using the ‘‘conditional formatting’’ functionalities
of Excel. These nonconformities should then be investigated
as required by the organization’s Quality Management Sys-
tem (QMS) as part of biobank accreditation.
In addition to columns with a ‘‘Z’’ option (‘‘Other’’), text
columns are provided, allowing recording of more detailed
information in cases where other specifications than those
listed in the SPREC were applied. If a value is unknown, then
‘‘unknown’’ should be entered.
FIG. 1. The elements and their relationships needed for automated SPREC calculation for fluid samples.
FIG. 2. The elements and their relationships needed for automated SPREC calculation for solid samples.
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The ‘‘Statistics’’ worksheet displays summary statistics
about the sample collection (e.g., number and percentage of
samples per code type, average, minimum, maximum and
median for selected time spans) related to selected SPREC
items (e.g., warm/cold ischemia time and fixation time for
solid samples). This summary sheet also allows the contin-
uous automated calculation of key performance indicators
(KPI), as required by quality norms. An example is shown
for the percentage of solid samples in the collection with
warm ischemia times below 30min (Fig. 3). For example, a
report can be generated stating the percentage of solid
samples in the collection with warm ischemia times below 30
minutes. Reports of variables of interest can be programmed
as required by the user. The Excel tool is available on http://
www.isber.org/SPRECtools.cfm.
Although SPRECalc is a stand-alone tool, the final SPREC
can be imported into a biobank database at regular intervals.
This solution provides a simple way of integrating the
SPREC into custom software, since no data logic or drop-
down lists need to be created. It is also possible to combine
the SPREC tools described here, the SPRECalc and SPREC-
ware, for generating and encoding SPRECs, respectively.
SPREC Interface with Reporting
Recommendations
A recent publication7 proposed reporting recommenda-
tions : Biospecimen Reporting for Improved Study Quality
(BRISQ). These recommendations include the type of infor-
mation that should be reported in scientific publications and
regulatory submissions based on work with biospecimens.
Whereas these recommendations present the different data
items that should be reported, they do not provide a stan-
dardized way of reporting them. The SPREC provides this
standardized format and can be efficiently used to fulfill all of
the BRISQ requirements that relate to in vitro variables: cov-
ering the workflow between the time of specimen collection
and long-term storage. Table 4 presents the interface between
the BRISQ and the seven basic SPREC elements (Table 4).
Conclusion
SPREC version 2.0 includes several new options, mainly
new sample types and additional storage conditions. Devel-
opment of the SPREC version 2.0 was based on valuable input
from many different biobanks worldwide that had previously
implemented SPREC version 1.0. Furthermore, we describe
readily accessible tools that facilitate implementation of SPREC
in biobank databases and fulfill requirements of the BRISQ.7
Glossary
Additives, urine: The most common urine preservatives are
boric acid, tartaric acid, or ascorbic acid. They reduce the risk
of bacterial overgrowth and specimen decomposition. Pre-
servation at room temperature ranges from 24 to 72 hours.
Table 3. Date Items for Automatic SPREC Calculation
Fluid Samples Solid Samples
Type of sample Type of sample
Type of primary sample container Type of collection
Collection time Vascular clamping time at surgery (denotes beginning of
warm ischemia)
Time of first centrifugation start Time of collection/Time of excision (denotes end of warm
ischemia time and beginning of cold ischemia time)
Sample temperature between collection and first
centrifugation
Fixation/stabilization type
First centrifugation speed Fixation start time (denotes end of cold ischemia time for
fixed tissue)
First centrifugation brake Fixation end time (alternatively for automated processes:
program start time, program type with related duration)
First centrifugation temperature Fixation end time (alternatively for automated processes:
program start time, program type with related duration)
Time of first centrifugation start1 Temperature of long term storage
Time of first centrifugation end (or duration of first
centrifugation)
Type of container of long term storage
Second centrifugation speed
Second centrifugation brake
Second centrifugation temperature
Time of second centrifugation start
Time of second centrifugation end2 (or duration of second
centrifugation)
Time of putting into temporary storage
Temperature of temporary storage
Time of putting into long term storage
Sample Temperature between end of last centrifugation and
putting into long term storage
Temperature of long term storage
Type of container of long term storage
1Time of freezing in the case of PAXgene.
2Time of last washing centrifugation in the case of viable cells.
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Buffy coat: The layer of white cells that forms between the
layer of red cells and the plasma when unclotted blood is
centrifuged or allowed to stand.
Cell preparation tube: Blood collection tube containing cell
separation media in the form of gel and/or filter.
Cryotubes: High density polypropylene tubes manufactured
to withstand ultra-low temperature conditions.
Dissociated tissue: Tissue that has undergone mechanical (e.g.,
scalpel) or chemical (e.g., protein digestion) separation, al-
lowing whole cells to be retrieved.
Disrupted tissue: Tissue that has undergone mechanical (e.g.,
sonication, freeze-thaw) or chemical (e.g., lysis buffer) cel-
lular disintegration.
Long-term storage: Storage of samples at their final desti-
nation temperature after possible temporary storage at
conditions, imposed by technical (e.g., overnight storage
of viable cells at - 80C before transfer into liquid nitro-
gen) or logistical (e.g., overnight storage of serum at
- 20C before transfer to - 80C in central storage facility)
reasons.
Pre-centrifugation delay: Time between collection and first
centrifugation of the samples. In the case of PAXgene
tubes, this corresponds to the delay between blood collection
and freezing of the tube (in this case, equivalent of ‘‘pre-
processing’’ delay). In the case of no centrifugation at all, the
‘‘pre-centrifugation delay’’ corresponds to the delay between
collection time and start of long-term storage.
Post-centrifugation delay: Time between the last centrifugation
and storage of the samples. In the case of viable cells, this
corresponds to the delay between the last washing
Table 4. Comparison of the BRISQ
and SPREC Data Elements
BRISQ data element SPREC data element
Biospecimen type Sample type
Anatomical site NI [not included]
Disease status of patients OS [out of scope]
Clinical characteristics of patients OS
Vital state of patients Type of collection
Clinical diagnosis of patients OS
Pathology diagnosis OS
Collection mechanism Type of primary container
Pre-centrifugation delay
Centrifugation
Second centrifugation
Post-centrifugation delay
Type of collection
Warm ischemia time
Cold ischemia time
Type of stabilization Type of primary container
Type of collection
Type of long-term preservation Fixation/stabilization type
Fixation time
Long-term storage
Constitution of preservative Fixation/stabilization type
Storage temperature Long-term storage
Storage duration NI
Shipping temperature NI
Composition assessment
and selection
OS
BRISQ data elements that are out of scope (OS) are in vivo- or
pathology-related elements: These are not considered to be SPREC
elements. BRISQ data elements that are not included (NI) are those
that relate to events during long term storage. The SPREC covers
processes until the specimens are placed in long term storage.
FIG. 3. Screenshot of SPRECalc statistics function.
SPREC: SAMPLE PREANALYTICAL CODE VERSION 2.0 373
centrifugation and the time of cryopreservation. In the case
of PAXgene tubes, the ‘‘post-centrifugation delay’’ is not
applicable. In the case of no centrifugation at all, the ‘‘post-
centrifugation delay’’ is not applicable.
Programmable freezing: Freezing in either a programmable
rate freezer or alternative solutions such as Mr Frosty.
Puncture: Surgical piercing of an anatomical tissue to obtain
material for clinicopathological examination. Includes cis-
ternal puncture, lumbar puncture, spinal puncture, sternal
puncture.
Room Temperature: Defined as 18C–28C.
Temporary Storage: Initial-term storage in conditions different
from the long-term storage conditions.
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